Sensei Biotherapeutics IncNASDAQ:SNSE
- LAST PRICE0.9806
- TODAY'S CHANGE (%)-0.0023 (-0.2340%)
- Bid / Lots0.9900/ 84
- Ask / Lots1.0100/ 1
- Open / Previous Close0.9400 / 0.9829
- Day Range
- 52 Week Range
- Volume5,407
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SNSE |
|---|---|---|
| 09:32 ET | 4169 | 0.933 |
| 09:34 ET | 920 | 0.9806 |
Apr 9, 2024
Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference, from 7:30AM ET on Tuesday Apr 09, 2024 by Dow Jones
7:30AM ET on Tuesday Apr 09, 2024 by Dow Jones
Apr 4, 2024
Mar 22, 2024
Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium, from 7:30AM ET on Friday Mar 22, 2024 by Dow Jones
7:30AM ET on Friday Mar 22, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Sensei Biotherapeutics Inc | 24.6M | -0.8x | --- |
UNITY Biotechnology Inc | 25.3M | -0.5x | --- |
Lisata Therapeutics Inc | 23.7M | -1.0x | --- |
Iterum Therapeutics PLC | 23.5M | -0.5x | --- |
Cardio Diagnostics Holdings Inc | 23.5M | -1.3x | --- |
Bullfrog AI Holdings, Inc. | 23.7M | -3.2x | --- |
Company Information
Sensei Biotherapeutics, Inc. is a clinical-stage immuno-oncology company, which is focused on the discovery and development of therapeutics for cancer patients. Through its Tumor Microenvironment Activated biologics (TMAb) platform, the Company develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Its lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation checkpoint selectively within the low pH tumor microenvironment. It is also developing SNS-102, a conditionally active monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4); SNS-103, a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), CD39; and SNS-201, a conditionally active VISTAxCD28 bispecific antibody.
Contact Information
- Headquarters
- 1405 Research Blvd, Suite 125ROCKVILLE, MD, United States 20850
- Phone
- 240-243-8000
- Fax
- 302-531-3150
Executives
- Independent Chairman of the Board
- William Ringo
- President, Chief Executive Officer, Director
- John Celebi
- Chief Scientific Officer
- Edward Van Der Horst
- Chief Business Officer
- Patrick Gallagher
- Independent Director
- Jessie English
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $24.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 25.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.21 |
Book Value | $2.59 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
